盤中異動 | 騰盛博藥-Ｂ盤中下跌8%，報於14.7港元
2022年1月31日9時33分，騰盛博藥-Ｂ(HK02137)盤中下跌8%，報於14.7港元，成交額達202.22萬港元，換手率達到0.01%。
1月20日訊，1月20日騰盛博藥-B(02137.HK)宣佈，於2022年1月20日，公司根據首次公開發售後股份獎勵計劃自願(i)向AMLOneUG(有限責任)(就Bouchon博士向公司提供的服務而言)授出8.4萬份受限制股份單位；(ii)向MurphyJr博士授出4.2萬份受限制股份單位、向Tang女士授出4.2萬份受限制股份單位、向徐耀華授出4.2萬份受限制股份單位及向Alton先生授出4.2萬份受限制股份單位；及(iii)向78名承授人(包括公司僱員及高級管理層)授出合共363.825萬份受限制股份單位，惟須待彼等接納。亦宣佈，於2022年1月20日，公司建議根據首次公開發售後股份獎勵計劃於授出日期向Hong博士授出91.1萬份受限制股份單位及向羅永慶先生授出60.7萬份受限制股份單位，惟須待接納及獲獨立股東於股東特別大會上批準。
12月13日，中金：騰盛博藥-B(02137)新冠中和抗體國內獲批上市，目標價升30%至52港元。
盈立趨勢長盈模型最近一次交易信號，2022年1月7日出現觀望信號，觸發價格爲29.6港元（信號僅供參考）。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
